Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Mease, Philip, Coates, Laura C, Helliwell, Philip S, Stanislavchuk, Mykola, Rychlewska-Hanczewska, Anna, Dudek, Anna, Abi-Saab, Walid, Tasset, Chantal, Meuleners, Luc, Harrison, Pille, Besuyen, Robin,Language:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(18)32483-8
Date:
October, 2018
File:
PDF, 606 KB
english, 2018